SLQT

Business Context and Reporting Period

SelectQuote, Inc. (SLQT) is a technology-enabled, direct-to-consumer distribution platform for insurance policies and healthcare services. The company operates through three reportable segments: Senior (Medicare-related products), Healthcare Services (including SelectRx pharmacy), and Life (term and final expense insurance). This Form 10-Q covers the quarterly period ended September 30, 2024 (Fiscal Q1 2025).

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 26% year-over-year, driven primarily by a 61% surge in Pharmacy revenue ($152.9 million) due to a 64% increase in SelectRx members. Commissions and other services revenue grew slightly by 1%.
• Profitability: While the Net Loss widened to $44.5 million from $31.1 million, Adjusted Segment EBITDA improved significantly to $18.6 million from $6.2 million. The Senior segment turned profitable with $7.7 million in Adjusted EBITDA compared to a loss of $1.3 million in the prior year.
• Expense Trends: Cost of goods sold for pharmacy revenue rose 54% to $129.5 million, reflecting medication costs associated with member growth. Selling, general, and administrative expenses increased 26% to $36.1 million, largely due to compensation costs and bad debt expense related to SelectRx.
• Liquidity: Cash and cash equivalents decreased by $32.2 million during the quarter, ending at $10.4 million. This decline was driven by net cash used in operating, investing, and financing activities, including $8.5 million in term loan principal payments.

Guidance, Outlook, Risks, and Unusual Items

• Debt Restructuring (Subsequent Event): On October 15, 2024, the company entered into an Eleventh Amendment to its Credit Agreement. This extended the maturity date of term loans, modified financial covenants, and facilitated a $100 million securitization transaction (ABS Facility) to pay down existing term loans. The company issued warrants to purchase 5.6 million shares to lenders in conjunction with this amendment.
• Liquidity Risk: Management stated it does not expect to generate sufficient cash flows from operations to meet milestone payments required by the Eleventh Amendment. Failure to secure additional financing or amend the credit facility could lead to default, necessitating asset sales or operational reductions.
• Legal Proceedings: The company is defending a consolidated securities class action lawsuit and a stockholder derivative suit. While management believes these will not have a material adverse effect, they could be costly and divert management attention.
• Segment Realignment: Effective July 1, 2024, the Auto & Home business was moved to an "All Other" category as it no longer met quantitative thresholds for separate reporting.

Investor Verification Checklist

• Covenant Compliance: Verify the company's ability to meet the modified financial covenants under the Eleventh Amendment and the milestone payments required to avoid interest rate increases.
• Securitization Impact: Assess the terms and costs of the new $100 million ABS Facility and the associated warrant issuance to lenders.
• Pharmacy Margins: Monitor the gross margin trajectory of the rapidly growing SelectRx segment, as COGS increased faster than revenue in the quarter.
• Cash Burn Rate: Evaluate the sustainability of the current cash position ($10.4 million) against quarterly operating cash outflows and debt service obligations.
• Legal Exposure: Track the status of the consolidated securities class action litigation for potential settlement costs or judgments.